## Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 10-K/A

BIOANALYTICAL SYSTEMS INC Form 10-K/A January 26, 2005

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-K/A (Amendment No. 1)

ended September 30, 2004	SECURITIES EXCHANGE ACT OF 1934 for the fisc
OR	
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF transition period from to	THE SECURITIES EXCHANGE ACT OF 1934 for the
Commission File Number BIOANALYTICAL SYS' (Exact name of the registrant as sp	TEMS, INC.
INDIANA	35-1345024
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
2701 KENT AVENUE WEST LAFAYETTE, INDIANA	47906
	(Zip code)
(Address of principal executive offices)	
(Address of principal executive offices) (765) 463-452	7

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2). YES NO

to such filing requirements for the past 90 days. YES

## Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 10-K/A

Based on the closing price on the NASDAQ stock market on January 10, 2005, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant is \$18,297,510. As of January 10, 2005, 4,869,502 shares of registrant's common shares were outstanding. No shares of registrant's Preferred Stock were outstanding as of January 10, 2004.

#### EXPLANATORY NOTE

The Company is filing this Amendment No. 1 to Annual Report on Form 10-K/A which was for the fiscal year ended September 30, 2004, solely to correct a typographical error in the Section 1350 Certifications contained in Exhibit 32. Except for the item noted above, no other information is being amended by this Form 10-K/A. The Company has not updated disclosures in this Form 10-K/A to reflect any event subsequent to the Company s filing of the original Form 10-K.

#### **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOANALYTICAL SYSTEMS, INC. (Registrant)

By: /s/ Peter T. Kissinger

Peter T. Kissinger President, Chairman and Chief Executive Officer

By: /s/ Michael R. Cox

Michael R. Cox Vice President, Finance, Chief Financial Officer and Treasurer

Date: January 25, 2005

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

Capacity

President, Chairman and Chief
Executive Officer and Director
(Principal Executive Officer)

January 25, 2005

Executive Officer

SIGNATURES 2

# Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 10-K/A

/s/ Michael R. Cox Michael R. Cox	Vice President, Finance, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)	January 25, 2005
Michael II. Cox		
/s/ William E. Baitinger	Director	January 25, 2005
William E. Baitinger		
/s/ David W. Crabb	Director	January 25, 2005
David W. Crabb		
Gayl W. Doster	- Director	January, 2005
/s/ Candice B. Kissinger	Director	January 25, 2005
Candice B. Kissinger		
/s/ Ronald E. Shoup	Director	January 25, 2005
Ronald E. Shoup		
	<ul><li>Director</li></ul>	January, 2005
Leslie B. Daniels		
	<ul><li>Director</li></ul>	January, 2005
W. Leigh Thompson		

SIGNATURES 3